Lv73
4730 积分 2023-01-12 加入
Cancer burden and control in China: landscape, trends and challenges
1天前
已完结
Letter to the Editor: Capivasertib plus abiraterone in PTEN-deficient metastatic hormone sensitive prostate cancer: CAPItello-281 phase III study
15天前
已关闭
[Chinese expert consensus on NGS-based probe design for tumor comprehensive genomic profiling testing (2026 edition)]
15天前
已完结
[Chinese expert consensus on NGS-based probe design for tumor comprehensive genomic profiling testing (2026 edition)]
19天前
已完结
[China lymphoma diagnosis and treatment guideline (2026 edition)]
1个月前
已完结
A Distinctive DICER1-Related Wilms-Like Uterine Tumor: A Report of Eight Cases
1个月前
已关闭
Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study
2个月前
已完结
[Consensus on clinical diagnosis and treatment of breast cancer with low expression and ultralow expression of HER-2 (2025 edition)]
2个月前
已完结
[Consensus on clinical diagnosis and treatment of breast cancer with low expression and ultralow expression of HER-2 (2025 edition)]
2个月前
已关闭
A comprehensive review of immune checkpoint inhibitors for cancer treatment
2个月前
已完结
皖公网安备34019202002308
